First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

Han, Ji‐Youn; Park, Keunchil; Kim, Sang‐We; Hyeong Lee, Ki; Young Kim, Hyae; Tae Kim, Heung; Ahn, Myung‐Ju; Yun, Tak; Seok Ahn, Jin; Suh, Cheolwon; Lee, Jung‐Shin; Jin Yoon, Sung; Hee Han, Jong; Lee, Jae‐Won; Jung Jo, Sook; Soo Lee, Jin

doi:10.1200/jco.2011.36.8456

Public

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

Published in Journal of Clinical Oncology • Feb 28, 2012

Authors:

Ji‐Youn Han

Keunchil Park

Sang‐We Kim

Abstract

PURPOSE: Gefitinib has shown high response rate and improved progression-free survival (PFS) in never-smokers with lung adenocarcinoma (NSLAs). We compared efficacy of gefitinib with gemcitabine and cisplatin (GP) chemotherapy in this group of patients as first-line therapy. PATIENTS AND METHODS: In...

Subject

Medicine

Gemcitabine

Oncology

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!